Global Atrial Fibrillation (AF) Market Report 2022-2027: AI Comes to the Fore in Diagnosing and Managing Arrythmias / Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation

10 Jun 2022
www.prnewswire.com
CollaborateAcquisition
DUBLIN, June 10, 2022 /PRNewswire/ -- The "Global Atrial Fibrillation Market - Treatment Types and End-User Facilities" report has been added to
ResearchAndMarkets.com's offering.
The report reviews, analyzes and projects the global Atrial Fibrillation market for the period 2018-2027 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2022 through 2027 with a special focus on y-o-y growth for 2019, 2020 and 2021
Atrial Fibrillation (AF) is the most common arrhythmia, which can lead to stroke, peripheral embolization, heart failure and other unfavorable outcomes. While the incidence of AF among the general population has been found to be at about 2.3%-3.4%, this registers a significant increase in patients with pulmonary disease, critical illness or systemic inflammatory response syndrome, with devastating clinical impact.
A number of recent epidemiological studies have established a greater risk of AF and new-onset AF among patients with COVID-19, though the results have been quite inconsistent. The literature available thus far has indicated that AF or new-onset AF can have a substantial association with the worst outcomes, viz., mortality, in patients with COVID-19.
Apart from the recent development of COVID-19 and its effect on AF, other factors that increase the risk of this condition include growing worldwide prevalence of obesity and heart diseases. The rise in the number of AF cases is fueling the market for treating this disease, though at the same time posing a crushing burden on the economies of several countries because of the high treatment cost involved.
Research Findings & Coverage
Global Atrial FibrillationFibrillation market is analyzed in this report with respect to treatment type/sub-type, end-user facilities
The study exclusively analyzes the market size of each treatment type/sub-type and end-user facility of Atrial Fibrillation by all major geographic regions/countries
Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
Revolutionary Catheter Ablation Technologies for AF Take Centerstage
Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
Major companies profiled - 19
The industry guide includes the contact details for 70 companies
Product Outline
The report analyzes the market for the following key treatment types/sub-types of Atrial Fibrillation:
Non-Pharmacological Treatment
Catheter Ablation
Electric Cardioversion
Pharmacological Treatment
Blood Thinners
Heart Rate Drugs
Heart Rhythm Drugs
End-User Facilities of Atrial Fibrillation analyzed in this study comprise the following:
Ambulatory Surgical Centers
Hospitals
KEY BUSINESS & PRODUCT TRENDS
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLXT LAAC Device
Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
Acutus Medical's Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium
Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System
Medtronic to Acquire Affera
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
Biosense Webster Announces Completion of Atrial Fibrillation Cases Using Novel HELIOSTART Balloon Ablation Catheter
New Data & Innovations: Heart Rhythm 2021
BIOTRONIK Expands Range of Peripheral Introducer Sheaths
CardioFocus-Announces-Agreement-to-Acquire-Intellectual-Property-Press-Release.pdf
Late-Breaking Data Shows Abbott's AmplatzerT AmuletT Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman? Device for People With Atrial Fibrillation at Risk of Stroke
Abbott's AmplatzerT AmuletT Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
AcQMap 8, Acutus Medical's Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark
Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless Pacemaker
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Abbott Receives European And Canadian Approval For AmplatzerT Steerable Delivery Sheath To Optimize Left Atrial Appendage Closure Procedures For People At Risk Of Stroke
Medtronic Receives FDA Expanded Approval for Arctic FrontT Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Abbott Introduces Jot DxT Insertable Cardiac Monitor, Designed To Reduce Data Burden And Improve Accurate Diagnosis Of Difficult-To-Detect Abnormal Heart Rhythms
AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias
New Data & Innovations: Heart Rhythm 2021
BIOTRONIK's Cardiac Monitor Receives Prestigious Award
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLXT Left Atrial Appendage Closure Device
CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021
CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care
Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes
Siemens Healthineers Receives CE Mark for the ACUSON AcuNav Volume ICE Catheter
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate FORCE Sensing Ablation System
Japan Lifeline Finalizes Supply Agreement for Pulsed Electric Field Ablation Catheter for U.S. Market
Acutus Medical Announces FDA Clearance of AcQCrossT, a Full Suite of Universal Transseptal Crossing Devices
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate FORCE Sensing Ablation System
AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
Acutus Medical Receives Vizient Innovative Technology Contract
Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
CardioFocus Announces Expanded Partnership With Japan Lifeline
CardioFocus Announces Expanded Distribution Partnership With MicroPortT CRM To Include Spain And Portugal
Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation
Acutus Medical Announces CE Mark and European Launch of AcQCrossT Transseptal System, a Fully Integrated Family of Transseptal Crossing Products
CardioFocus Announces 10,000 Patients Treated Worldwide
First Clinical Implantation of MicroPort Left.
Abbott Introduces Next-Generation 3d Cardiac Mapping Platform In Europe And Australia
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
Acutus Medical Launches AcQBlate Force Sensing Ablation System in Europe
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter
Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical Results
Medtronic Gains FDA Clearance, CE Mark for LINQ IIT Insertable Cardiac Monitor (ICM)
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
Medtronic MicraT AV Receives CE Mark
New Alliance Maps the Way in Electrophysiology
CardioFocus Announces US FDA Approval of HeartLight X3 System for the Treatment of Atrial Fibrillation
GE Healthcare and Preventice Solutions Collaborate to Connect the Heart, the Hospital and the Home Seamlessly
Bristol Myers Squibb - The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis
KEY MARKET TRENDS
Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
Atrial Fibrillation Treated Successfully through Pulsed Field Ablation
Revolutionary Catheter Ablation Technologies for AF Take Centerstage
MARKET PLAYERS
Major Market Players
Abbott Laboratories (United States)
Acutus Medical, Inc. (United States)
Atricure, Inc. (United States)
Biosense Webster, Inc. (United States)
Boston Scientific Corporation (United States)
Bristol-Myers Squibb Co. (United States)
Cardiofocus, Inc. (United States)
GE Healthcare (United States)
Pfizer Inc. (United States)
EUROPE
Major Market Players
Acesion Pharma (Denmark)
Afreeze GmbH (Austria)
Medtronic PLC (Ireland)
Osypka AG (Germany)
Major Market Players
Cathrx Ltd (Australia)
For more information about this report visit https://www.researchandmarkets.com/r/w5xggg
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.